CONNECTIVE TISSUE GROWTH FACTOR-2

Abstract: The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing.

Description: CONNECTIVE TISSUE GROWTH FACTOR-2 This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is connective tissue growth factor-2 sometimes hereinafter referred to as "CTGF- 2". The invention also relates to inhibiting the action of such polypeptides. The CTGF polypeptides are structurally and functionally related to a family of growth factors which include IGF (insulin-like growth factor), PDGF (platelet-derived growth factor), and FGF (fibroblast growth factor). This emerging family of secreted proteins are a group of cysteine-rich proteins. This group of growth factors are important for normal growth, differentiation, morphogenesis of the cartilaginous skeleton of an embryo and cell growth. Among some of the functions that have been discovered for these growth factors are wound healing, tissue repair, implant fixation and stimulating increased bone mass. The extended superfamily of growth factors include TGF (transforming growth factor), bone morphogenic factors, and activins, among others. The most well-known growth factor, TGF exerts a number of different effects on a variety of cells. For example, TGF- / S can inhibit the differentiation of certain cells of mesodermal origin (Florini, J.R. et al., J. Biol. Chem.. 261:1659-16513 (1986) induced the differentiation of others (Seyedine, S.M. et al., PNAS USA. 82:2267-2271 (1987) and potently inhibit proliferation of various types of epithelial cells, (Tucker, R.F., Science. 226:705-705 (1984)). This last activity has led to the speculation that one important physiological role for TGF-β is to maintain the repressed growth state of many types of cells. Accordingly, cells that lose the ability to respond to TGF-/3 are more likely to exhibit uncontrolled growth and become tumorigenic. Accordingly, due to a ino acid sequence homology the polypeptide of the present invention is a member of this extended family of growth factors which has many effects on a variety of different tissues. In accordance with one aspect of the present invention, there is provided a novel mature polypeptide which is CTGF-2, as well as fragments, analogs and derivatives thereof. The polypeptide of the present invention is of human origin. In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides. In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptide by recombinant techniques. In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptide, or polynucleotide encoding such polypeptide for therapeutic purposes, for example, enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides. In accordance with yet another aspect of the present invention, there are provided antagonist/inhibitors to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of CTGF dependent tumor growth. These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein. The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims. Figure 1 depicts the cDNA sequence and corresponding deduced amino acid sequence of CTGF-2. The standard one- letter abbreviation for amino acids is used. Figure 2 is an amino acid comparison between CTGF-2 (top) and Cyr61 ((bottom) illustrating the amino acid sequence homology. Figure 3 is. an amino acid comparison between CTGF-2 (top) and mouse CTGF (bottom) illustrating the amino acid sequence homology. Figure 4 depicts the results of a Northern Blot analysis of CTGF-2. In accordance with an aspect of the present invention, there is provided an isolated nucleic acid (polynucleotide) which encodes for the mature polypeptide having the deduced amino acid sequence of Figure 1 or for the mature polypeptide encoded by the cDNA of the clone deposited as ATCC Deposit No. 75804. The polynucleotide of this invention was discovered in a cDNA library derived from Human fetal lung. It is structurally related to the IGF and PDGF family. It contains an open reading frame encoding a protein of approximately 375 amino acid residues of which approximately the first 24 amino acids residues are the putative leader sequence such that the putative mature protein comprises 201 amino acids. The protein exhibits the highest degree of homology to Mouse CTGF with 49% identity and 67% similarity and to Cyrβl with 89% identity and 93% similarity. Cyr61 is a growth factor- inducible immediate early gene initially identified in serum- stimulated mouse fibroblasts. It encodes a member of an emerging family of cysteine-rich secreted proteins that includes a connective tissue growth factor (O'Brien and Lau, L.F., Cell Growth Differ., 3:645-54 (1992)). The polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double- stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequence shown in Figure 1 or that of the deposited clone or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the DNA of Figure 1 or the deposited cDNA. The polynucleotide which encodes for the mature polypeptide of Figure 1 or for the mature polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding sequence 5 ' and/or 3 ' of the coding sequence for the mature polypeptide. Thus, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence. The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the polypeptide having the deduced amino acid sequence of Figure 1 or the polypeptide encoded by the cDNA of the deposited clone. The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide. Thus, the present invention includes polynucleotides encoding the same mature polypeptide as shown in Figure 1 or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of Figure 1 or the polypeptide encoded by the cDNA of the deposited clone. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants. As hereinabove indicated, the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence shown in Figure 1 or of the coding sequence of the deposited clone. As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide. The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa- histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al.. Cell, 37:767 (1984)). The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 50% and preferably 70% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides . As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the mature polypeptide encoded by the cDNA of Figure 1 or the deposited cDNA. The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted. The present invention further relates to a CTGF-2 polypeptide which has the deduced amino acid sequence of Figure 1 or which has the amino acid sequence encoded by the deposited cDNA, as well as fragments, analogs and derivatives of such polypeptide. The terms "fragment," "derivative" and "analog" when referring to the polypeptide of Figure 1 or that encoded by the deposited cDNA, means a polypeptide which retains essentially the same biological function or activity as such polypeptide. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide. The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide. The fragment, derivative or analog of the polypeptide of Figure 1 or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein. The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity. The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally- occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Host cells are genetically engineered (transduced or transformed or tranεfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformantε or amplifying the CTGF-2 genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host. The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonucleaεe site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art. The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli. lac or trp. the phage lambda P L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli. The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli. Streptomyces. Salmonella typhimuriu ; fungal cells, such as yeast; insect cells such as Drosophila and Sf9; animal cells such as CHO, COS or Bowes melanoma; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pRGl, pDIO, phagescript, psiX174, pBluescript SK, pbskε, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene) ; pTrc99a, pKK223- 3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXTl, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia) . However, any other plasmid or vector may be used as long as they are replicable and viable in the host. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are PKK232-8 and PCM7. Particular named bacterial promoters' include lad, lacZ, T3, T7, gpt, lambda P R , P L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinaεe, early and late SV40, LTRε from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, εuch as a mammalian cell, or a lower eukaryotic cell, such as a yeast -10- SUBSTITUTE SHEET (RULE 25) cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE- Dextran mediated transfection, or electroporation. (Davis L., Dibner, M. , Battey, I., Basic Methods in Molecular Biology, (1986)). The constructε in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expreεεed in mammalian cellε, yeaεt, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hostε are deεcribed by Sambrook, et al.. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the diεcloεure of which iε hereby incorporated by reference. Tranεcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elementε of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phoεphoglycerate kinaεe (PGK), ct-factor, acid phoεphatase, or heat shock proteins, among others. The heterologous εtructural sequence is assembled in appropriate phase with translation initiation and termination sequenceε, and preferably, a leader εequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristicε, e.g., εtabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signalε in operable reading phaεe with a functional promoter. The vector will compriεe one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hoεtε for transformation include E. coli. Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudo onaε, Streptomyceε, and Staphylococcus, although others may also be employed as a matter of choice. As a representative but nonlimiting example, uεeful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppεala, Sweden) and GEM1 (Promega Biotec, Madiεon, WI, USA). Theεe pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate meanε (e.g., temperature εhift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical diεruption, or use of cell lyεing agentε, εuch methodε are well know to those skilled in the art. Various mammalian cell culture systemε can alεo be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lineε. Mammalian expreεεion vectorε will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, εplice donor and acceptor εiteε, tranεcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequenceε derived from the SV40 splice, and polyadenylation siteε may be uεed to provide the required nontranscribed genetic elements. The CTGF-2 polypeptides can be recovered and purified from recombinant cell cultures by methodε including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as neceεεary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial ethionine amino acid residue. The CTGF-2 polypeptides of the present invention may be used to enhance the repair of connective and support tissue. For example CTGF-2 may be used to treat skin disorders such as injuries, acne, aging, UV damage or burns. CTGF-2 may also be used to improve the cosmetic appearance of the skin, for example, by treating wrinkled εkin. CTGF-2 may alεo be uεed to promote the attachment, fixation and εtabilization of tiεsue implants, for example, a prostheεiε and other implantε inεerted during reconstructive surgery. The CTGF-2 polypeptide of the present invention may be used in the healing of external woundε, by promoting growth of epithelial and connective tissueε and the εynthesiε of total protein and collagen. CTGF-2 may be applied in the area of injured or depleted boneε, with regeneration occurring by promoting the growth of connective tiεεue, bone and cementum and by stimulating protein and collagen synthesiε which iε eεpecially useful for periodontal diseaεe. The polypeptide of the preεent invention is also useful for identifying other molecules which have similar biological activity. For example, the coding region of the CTGF-2 gene iε iεolated by uεing the known DNA εequence to εynthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention are used to screen a library of human cDNA, genomic DNA to determine which members of the library the probe hybridizes to. The polypeptides may also be employed in accordance with the present invention by expression of such polypeptides in vivo r which is often referred to as "gene therapy." Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) encoding a polypeptide ex vivo , with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle containing RNA encoding a polypeptide of the present invention. Similarly, cells may be engineered in vivo for expression of a polypeptide in vivo by, for example, procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the preεent invention may be administered to a patient for engineering cells in vivo and expreεsion of the polypeptide in vivo . These and other methods for administering a polypeptide of the present invention by such method should be apparent to thoεe εkilled in the art from the teachingε of the preεent invention. For example, the expreεεion vehicle for engineering cellε may be other than a retroviruε, for example, an adenoviruε which may be used to engineer cellε in vivo after combination with a suitable delivery vehicle. The polypeptideε of the present invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the polypeptide, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should suit the mode of adminiεtration. The invention alεo provideε a pharmaceutical pack or kit compriεing one or more containerε filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Asεociated with such container(s) can be a notice in the form preεcribed by a governmental agency regulating the manufacture, use or εale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the preεent invention may be employed in conjunction with other therapeutic compounds. The pharmaceutical compositions may be administered in a convenient manner such as by the topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes. CTGF-2 is administered in an amount which is effective for treating and/or prophylaxis of the specific indication. In general, CTGF-2 will be adminiεtered in an amount of at leaεt about 10 μg/kg body weight and in moεt caεeε CTGF-2 will be adminiεtered in an amount not in excess of about 8 mg/Kg body weight per day. In most caseε, the doεage iε from about 10 μg/kg to about 1 mg/kg body weight daily, taking into account the routeε of adminiεtration, εymptomε, etc. The εequences of the present invention are also valuable for chromosome identification. The εequence iε εpecifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there iε a current need for identifying particular εites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomeε according to the present invention is an important first step in correlating those sequences with genes asεociated with disease. Briefly, sequences can be mapped to chromosomeε by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the cDNA is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification procesε. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomeε. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment. PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Uεing the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomeε and preεelection by hybridization to conεtruct chromoεome εpecific-cDNA libraries. Fluorescence in situ hybridization (FISH) of a cDNA clones to a metaphase chromoεomal εpread can be uεed to provide a preciεe chromosomal location in one step. This technique can be used with cDNA as εhort aε 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requireε use of the clones from which the EST was derived, and the longer the better. For example, 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not neceεεary to get good results a reasonable percentage of the time. For a review of this technique, see Verma et al.. Human Chromosomes: a Manual of Basic Techniques, Perga on Presε, New York (1988). Once a εequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) . The relationship between genes and diseaεeε that have been mapped to the same chromosomal region are then identified through linkage analyεiε (coinheritance of phyεically adjacent geneε). Next, it iε neceεεary to determine the differenceε in the cDNA or genomic εequence between affected and unaffected individualε. If a mutation iε obεerved in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the diseaεe. With current reεolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region asεociated with the diεease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb). The polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments. Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptideε itεelf. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tisεue expreεsing that polypeptide. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV- hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liεε, Inc., pp. 77-96). Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce εingle chain antibodieε to immunogenic polypeptide products of this invention. This invention provides a method for identification of the receptor for the CTGF-2 polypeptide. The gene encoding the receptor can be identified by expression cloning. Briefly, polyadenylated RNA is prepared from a cell responsive to CTGF-2, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to CTGF-2. Transfected cellε which are grown on glass slides are exposed to labeled CTGF-2. The CTGF-2 can be labeled by a variety of means including iodidation or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and rescreening proceεs, eventually yielding a single clone that encodes the putative receptor. As an alternative approach for receptor identification, labeled ligand can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Crosε- linked material iε reεolved by PAGE and expoεed to x-ray film. The labeled complex containing the CTGF-2-receptor can be exciεed, reεolved into peptide fragments, and subjected to protein microsequencing. The amino acid εequence obtained from microεequencing would be uεed to deεign a εet of generate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor. This invention also provides a method of screening drugs to identify those which enhance or block interaction of CTGF- 2 with its receptor. An agonist is a compound which increases the natural biological functions of CTGF-2 and an antagonist inhibits these functions. Aε an example, a mammalian cell or membrane preparation expreεsing the CTGF-2 receptor would be incubated with labeled CTGF-2 in the presence of drug. The ability of the drug to enhance or block this interaction could then be measured. Alternatively, the response of a known second meεεenger system following interaction of CTGF-2 and its receptor would be meaεured compared in the presence or absence of the drug. Such second mesεenger εystems include but are not limited to, cAMP guanylate cyclaεe, ion channelε or phoεphoinositide hydrolyεiε. The preεent invention iε alεo directed to antagonist/inhibitor molecules of the polypeptides of the present invention, and their use in reducing or eliminating the function of CTGF-2. An example of an antagonist is an antibody or in some cases, an oligonucleotide, which binds to the CTGF-2 polypeptide. Alternatively, antagonists include closely related proteinε that have loεt biological function and thereby prevent the action of CTGF-2 since receptor siteε are occupied. Antisense technology may be employed to decrease the level of in vivo circulation of CTGF-2. Antisenεe technology can be uεed to control gene expreεsion through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the mature polypeptides of the present invention, is used to design an antisenεe RNA oligonucleotide of from about 10 to 40 baεe pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in tranεcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al. Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991)), thereby preventing tranεcription and the production of CTGF-2. The antiεenεe RNA oligonucleotide hybridizeε to the mRNA in vivo and blocks translation of the mRNA molecule into CTGF-2 (antiεenεe - Okano, J. Neurochem. , 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). The oligonucleotides deεcribed above can alεo be delivered to cellε such that the antisenεe RNA or DNA may be expressed in vivo to inhibit production of CTGF-2. An example of an inhibitor is a small molecule which binds to the CTGF-2 receptors such that normal biological activity is prevented. Exampleε of εmall moleculeε include but are not limited to εmall peptideε or peptide-like moleculeε. The antagoniεt/inhibitors may be employed to prevent scar formation due to excesε proliferation of connective tissues and to prevent CTGF-2 dependent tumor growth. The antagonist/inhibitors may be employed in a composition with a pharmaceutically acceptable carrier, e.g., aε hereinabove deεcribed. The present invention also relates to an assay for identifying potential antagonist/inhibitorε εpecific to CTGF- 2. An example of such an assay combines CTGF-2 and a potential antagonist/inhibitor with membrane-bound CTGF-2 receptorε or recombinant CTGF-2 under appropriate conditionε for a competitive inhibition aεεay. CTGF-2 can be labeled, εuch aε by radio activity, εuch that the number of CTGF-2 moleculeε bound to the receptor can determine the effectiveness of the potential antagonist/inhibitor. The preεent invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All partε or amountε, unleεε otherwiεe specified, are by weight. In order to facilitate understanding of the following examples certain frequently occurring methodε and/or termε will be deεcribed. "Plasmids" are designated by a lower caεe p preceded and/or followed by capital letterε and/or numberε. The εtarting plaεmids herein are either commercially available, publicly available on an unrestricted basiε, or can be conεtructed from available plaεmids in accord with published procedureε. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan. "Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain εequenceε in the DNA. The various reεtriction enzymes used herein are commercially available and their reaction conditions, cofactorε and other requirementε were uεed aε would be known to the ordinarily εkilled artisan. For analytical purposes, typically 1 μg of plasmid or DNA fragment is uεed with about 2 unitε of enzyme in about 20 μl of buffer εolution. For the purpoεe of iεolating DNA fragmentε for plaεmid conεtruction, typically 5 to 50 μg of DNA are digeεted with 20 to 250 unitε of enzyme in a larger volume. Appropriate buffers and substrate amountε for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37"C are ordinarily used, but may vary in accordance with the supplier's instructionε. After digestion the reaction iε electrophoreεed directly on a polyacrylamide gel to isolate the desired fragment. Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel, D. et al . , Nucleic Acids Res., 8:4057 (1980). "Oligonucleotides" referε to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the preεence of a kinaεe. A εynthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated. "Ligation" refers to the procesε of forming phoεphodiester bonds between two double stranded nucleic acid fragmentε (Maniatis, T., et al.. Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase") per 0.5 μg of approximately equimolar amountε of the DNA fragmentε to be ligated. Unleεε otherwiεe εtated, tranεformation was performed as described in the method of Graham, F. and Van der Eb, A., Virology, 52:456-457 (1973). SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: LI, ET AL. (ii) TITLE OF INVENTION: Connective Tiεεue Growth Factor-2 (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN (B) STREET: 6 BECKER FARM ROAD (C) CITY: ROSELAND (D) STATE: NEW JERSEY (E) COUNTRY: USA (F) ZIP: 07068 (V) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 INCH DISKETTE (B) COMPUTER: IBM PS/2 (C) OPERATING SYSTEM: MS-DOS (D) SOFTWARE: WORD PERFECT 5.1 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: Concurrently (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA (A) APPLICATION NUMBER: (B) FILING DATE: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: FERRARO, GREGORY D. (B) REGISTRATION NUMBER: 36,134 (C) REFERENCE/DOCKET NUMBER: 325800-129 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 201-994-1700 (B) TELEFAX: 201-994-1744 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 1128 BASE PAIRS (B) TYPE: NUCLEIC ACID (C) STRANDEDNESS: SINGLE (D) TOPOLOGY: LINEAR (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ATGAGCTCCC GAATCGTCAG GGAGCTCGCC TTAGTCGTCA CCCTTCTCCA CTTGACCAGG 60 GTGGGGCTCT CCACCTGCCC CGCTGACTGC CACTGCCCCC TGGAGGCGCC CAAGTGCGCG 120 CCGGGAGTCG GGCTGGTCCG GGACGGCTGC GGCTGTTGTA AGGTCTGCGC CAAGCAGCTC 180 AACGAGGACT GCAGAAAAAC GCAGCCCTGC GACCACACCA AGGGGCTGGA ATGCAACTTC 240 GGCGCCAGCT CCACCGCTCT GAAGGGGATC TGCAGAGCTC AGTCAGAGGG CAGACCCTGT 300 GAATATAACT CCAGAATCTA CCAAAACGGG GAAAGTTTCC AGCCCAACTG TAAACATCAG 360 TGCACATGTA TTGGATGGCG CCGGGGGGCT TGCATTCCTC TGTGTCCCCA AGAACTATCT 420 CCCCCCAACT TGGGCTGTCC CAACCCTCGG CTGGTCAAAG TTACCGGGCA GTGCTGCGAG 480 GAGTGGGTCT GTGACGAGGA TAGTATCAAG GACCCCATGG AGGACCAGGA CGGCCTCCTT 540 GGCAAGGGGC TGGGATTCGA TGCCTCCGAG GTGGAGTTGA CGAGAAACAA TGAATTGATT 600 GCAGTTGGAA AAGGCAGCTC ACTGAAGCGG CTCCCTGTTT TTGGAATGGA GCCTCGCATC 660 CTATACAACC CTTTACAAGG CCAGAAATGT ATTGTTCAAA CAACTTCATG GTCCCAGTGC 720 TCAAAGACCT GTGGAACTGG TATCTCCACA CGAGTTACCA ATGACAACCC TGAGTGCCGC 780 CTTGTGAAAG AAACCCGGAT TTGTGAGGTG CGGCCTTGTG GACAGCCAGT GTACAGCAGC 840 CTGAAAAAGG GCAAGAAATG CAGCAAGACC AAGAAATCCC CCGAACCAGT CAGGTTTACT 900 TACGCTGGAT GTTTGAGTGT GAAGAAATAC CGGCCCAAGT ACTGCGGTTC CTGCGTGGAC 960 GGCCGATGCT GCACGCCCCA GCTGACCAGG ACTGTGAAGA TGCGGTTCCC CTGCGAAGAT 1020 GGGGAGACAT TTTCCAAGAA CGTCATGATG ATCCAGTCCT CCAAATGCAA CTACAACTGC 1080 CCGCATGCCA ARGAAGCAGC GTTTCCCTTC TACAGGCTGT TCCAATGA 1128 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 375 AMINO ACIDS (B) TYPE: AMINO ACID (C) STRANDEDNESS: (D) TOPOLOGY: LINEAR (ϋ) MOLECULE TYPE: PROTEIN (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Ser Ser Arg lie Val Arg Glu Leu Ala Leu Val Val Thr Leu -20 -15 -10 Leu His Leu Thr Arg Val Gly Leu Ser Thr Cys Pro Ala Asp Cys -5 1 5 His Cyε Pro Leu Glu Ala Pro Lys Cyε Ala Pro Gly Val Gly Leu 10 15 20 Val Arg Asp Gly Cyε Gly Cys Cys Lys Val Cyε Ala Lys Gin Leu 25 30 35 Asn Glu Asp Cys Arg Lys Thr Gin Pro Cys Aεp His Thr Lys Gly 40 45 50 Leu Glu Cys Asn Phe Gly Ala Ser Ser Thr Ala Leu Lys Gly lie 55 60 65 Cyε Arg Ala Gin Ser Glu Gly Arg Pro Cyε Glu Tyr Asn Ser Arg 70 75 80 lie Tyr Gin Asn Gly Glu Ser Phe Gin Pro Asn Cys Lys His Gin 85 90 95 Cyε Thr Cys lie Gly Thp Arg Arg Gly Ala Cys lie Pro Leu Cys 100 105 110 Pro Gin Glu Leu Ser Leu Pro Asn Leu Gly Cys Pro Asn Pro Arg 115 120 125 Leu Val Lyε Val Thr Gly Gin Cys Cyε Glu Glu Trp Val Cys Asp 130 135 140 Glu Asp Ser lie Lys Asp Pro Met Glu Asp Gin Aεp Gly Leu Leu 145 150 155 Gly Lyε Gly Leu Gly Phe Aεp Ala Ser Glu Val Glu Leu Thr Arg 160 165 170 Aεn Aεn Glu Leu lie Ala Val Gly Lyε Gly Ser Ser Leu Lyε Arg 175 180 185 Leu Pro Val Phe Gly Met Glu Pro Arg lie Leu Tyr Aεn Pro Leu 190 195 200 Gin Gly Gin Lyε Cyε lie Val Gin Thr Thr Ser Trp Ser Gin Cyε 205 210 215 Ser Lyε Thr Cys Gly Thr Gly lie Ser Thr Arg Val Thr Asn Asp 220 225 230 Asn Pro Glu Cyε Arg Leu Val Lyε Glu Thr Arg lie Cys Gly Val 235 240 245 Arg Pro Cys Gly Gin Pro Val Tyr Ser Ser Leu Lys Lys Gly Lys 250 255 260 Lys Cys Ser Lys Thr Lys Lyε Ser Pro Glu Pro Val Arg Phe Thr 265 270 275 Tyr Ala Gly Cys Leu Ser Val Lys Lys Tyr Arg Pro Lys Tyr Cys 280 285 290 Gly Ser Cys Val Asp Gly Arg Cys Cys Thr Pro Gin Leu Thr Arg 295 300 305 Thr Val Lys Met Arg Phe Pro Cys Glu Asp Gly Glu Thr Phe Ser 310 315 320 Lys Asn Val Met Met lie Gin Ser Ser Lys Cys Asn Tyr Asn Cys 325 330 335 Pro Hiε Ala Aεn Glu Ala Ala Phe Pro Phe Tyr Arg Leu Phe Gin 340 345 350 Example 1 Cloning and expression of CTGF-2 in a baculoviruε expreεsion syεtem The DNA sequence encoding the full length CTGF-2 protein, ATCC # 75804, was amplified uεing PCR oligonucleotide primers corresponding to the 5' and 3' sequenceε of the gene: The 5' primer has the sequence CGCGGGATCCTGCGCGACACAATGAGCT and contains a BamHI restriction enzyme site (in bold) followed by 18 nucleotides resembling an efficient εignal for the initiation of translation in eukaryotic cells (J. Mol. Biol. 1987, 196. 947-950, Kozak, M. ) . The initiation codon for translation "ATG" is underlined. The 3' primer haε the εequence CGCGGGTACCAGGTAGCATTTAGTCCCTAA and contains the cleavage εite for the restriction endonucleaεe Aεp781 and 20 nucleotides complementary to the 3' non-translated εequence of the CTGF-2 gene. The amplified εequenceε were iεolated from a 1% agaroεe gel uεing a commercially available kit ("Geneclean", BIO 101 Inc., La Jolla, Ca.). The fragment waε then digeεted with the endonucleaεeε BamHI and Aεp781 and then purified by iεolation on a 1% agarose gel. This fragment iε deεignated F2. The vector pRGl (modification of pVL941 vector, discusεed below) iε used for the expresεion of the CTGF-2 protein using the baculovirus expression εyεtem (for review see: Summers, M.D. and Smith, G.E. 1987, A manual of methodε for baculoviruε vectorε and inεect cell culture procedureε, Texaε Agricultural Experimental Station Bulletin No. 1555). Thiε expreεεion vector containε the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosiε viruε (AcMNPV) followed by the recognition εiteε for the reεtriction endonucleaεes BamHI and Aεp781. The polyadenylation εite of the simian viruε (SV)40 iε used for efficient polyadenylation. For an eaεy εelection of recombinant viruses the beta-galactosidaεe gene from E.coli is inserted in the same orientation as the polyhedrin promoter followed by the polyadenylation signal of the polyhedrin gene. The polyhedrin εequenceε are flanked at both sides by viral sequences for the cell- mediated homologous recombination of cotranεfected wild-type viral DNA. Many other baculovirus vectors could be used in place of pRGl such aε pAc373, pVL941 and pAcIMl (Luckow, V.A. and Summers, M.D., Virology, 170:31-39). The plasmid was digested with the restriction enzymes BamHI and Asp781 and then dephoεphorylated uεing calf intestinal phosphatase b procedures known in the art. The DNA was then isolated from a 1% agarose gel. This vector DNA iε designated V2. Fragment F2 and the dephoεphorylated plasmid V2 were ligated with T4 DNA ligase. E.coli HB101 cells were then tranεformed and bacteri identified that contained the plasmid (pBacCTGF-2) with the CTGF-2 gene uεing the enzymes BamHI and Asp781. The εequence of the cloned fragment waε confirmed by DNA εequencing. 5 μg of the plasmid pBacCTGF-2 were cotransfected with 1.0 μg of commercially available linearized baculovirus ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA. ) using the lipofection method (Feigner et al. Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987)) . lμg of BaculoGold™ virus DNA and 5 μg of the plasmid pBacCTGF-2 were mixed in a εterile well of a microtiter plate containing 50 μl o serum free Grace'ε medium (Life Technologieε Inc., Gaithersburg, MD). Afterwards 10 μl Lipofectin plus 90 μl Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added dropwise to the Sf9 insect cellε (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1ml Grace' medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate was then incubated for 5 hours at 27°C. After 5 hourε the tranεfection εolution waε removed from the plate and 1 ml of Grace'ε inεect medium supplemented with 10% fetal calf serum waε added. The plate waε put back into an incubator and cultivation continued at 27°C for four days. After four days the supernatant was collected and a plaque assay performed similar as described by Summers and Smith (supra). As a modification an agarose gel with "Blue Gal" (Life Technologieε Inc., Gaithersburg) was used which allows an easy iεolation of blue stained plaques. (A detailed deεcription of a "plaque aεεay" can alεo be found in the user'ε guide for inεect cell culture and baculovirology distributed by Life Technologieε Inc., Gaithersburg, page 9-10). Four days after the serial dilution of the viruseε waε added to the cellε, blue εtained plaqueε were picked with the tip of an Eppendorf pipette. The agar containing the recombinant viruseε waε then reεuεpended in an Eppendorf tube containing 200 μl of Grace'ε medium. The agar waε removed by a brief centrifugation and the supernatant containing the recombinant baculoviruseε waε uεed to insect Sf9 cells seeded in 35 mm dishes. Four days later the εupernatantε of theεe culture dishes were harvested and then εtored a 4°C. Sf9 cellε were grown in Grace'ε medium εupplemented with 10% heat inactivated FBS. The cells were infected with the recombinant baculovirus V-CTGF-2 at a multiplicity of infection (MOI) of 2. Six hours later the medium waε removed and replaced with SF900 II medium minuε methionine and cyεteine (Life Technologieε Inc., Gaitherεburg) . 42 hours later 5 μCi of 35 S-methionine and 5 μCi 35 S cyεteine (Amerεham) were added. The cellε were further incubated for 16 hourε before the were harvested by centrifugation and the labelled proteins visualized by SDS-PAGE and autoradiography. Example 2 Expresεion of Recombinant CTGF-2 in COS cellε The expression of plasmid, CTGF-2 HA is derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2 ampicillin resistance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, a SV40 intron and polyadenylation εite. A DNA fragment encoding the entire CTGF-2 precursor and a HA tag fuεed in frame to its 3' end waε cloned into the polylinker region of the vector, therefore, the recombinant protein expreεεion is directed under the CMV promoter. The HA tag correspond to an epitope derived from the influenza hemagglutinin protein as previously described (I. Wilson, H. Niman, R. Heighten, A Cherenson, M. Connolly, and R. Lerner, 1984, Cell 37, 767). The infusion of HA tag to our target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope. The plasmid construction strategy is deεcribed aε followε: The DNA sequence encoding for CTGF-2, ATCC # 75804, waε constructed by PCR on the full-length clone using two primers: the 5 primer 5' AAAGGATCCACAATGAGCTCCCGAATC 3' contains a Bam HI site followed by 18 nucleotides of CTGF-2 coding sequence starting from the -3 position relative to the initiation codon; the 3' sequence 5' CGCTCTAGATTAAGCGTAGTCTGGGACGTCGTATGGGTATTGGAACAGCCTGTAGAAG 5' contain complementary εequenceε to an Xba I εite, tranεlation εtop codon, HA tag and the last 19 nucleotides of the CTGF-2 coding sequence (not including the stop codon). Therefore, the PCR product contains " a Bam HI site, CTGF-2 coding sequence followed by an HA tag fused in frame, a translation termination stop codon next to the HA tag, and an Xba I site. The PCR amplified DNA fragment and the vector, pcDNAI/Amp, wer digested with Bam HI and Xba I restriction enzymes and ligated. The ligation mixture was transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037) the transformed culture was plated on ampicillin media plates and reεiεtant colonies were selected. Plasmid DNA waε isolated from transformants and examined by reεtriction analysis for the presence of the correct fragment. For expresεion of the recombinant CTGF-2, COS cellε were tranεfected with the expreεεion vector by DEAE-DEXTRAN method. (J. Sambrook, E. Fritεch, T. Maniatiε, Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, (1989)). The expresεion of the CTGF-2 HA protein waε detected by radiolabelling and immunoprecipitation method. (E. Harlow, D. Lane, Antibodieε: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988)). Cells were labelled for 8 hours with 35 S-cysteine two dayε post transfection. Culture media were then collected and cells were lysed with detergent (RIPA buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50mM Tris, pH 7.5). (Wilson, I. et al. , Id. 37:767 (1984)). Both cell lysate and culture media were precipitated with a HA specific monoclonal antibody. Proteins precipitated were analyzed on 15% SDS-PAGE gels. Example 3 Expression pattern of CTGF-2 in human tiεsue Northern blot analysis was carried out to examine the levels of expression of CTGF-2 in human tissueε. Total cellular RNA εampleε were iεolated with RNAzol™ B εyεtem (Biotecx Laboratorieε, Inc. 6023 South Loop East, Houston, TX 77033). About lOμg of total RNA isolated from each human tisεue εpecified was separated on 1% agarose gel and blotted onto a nylon filter. (Sambrook, Fritsch, and Maniatiε, Molecular Cloning, Cold Spring Harbor Preεs, (1989)). The labeling reaction was done according to the Stratagene Prime-It kit with 50ng DNA fragment. The labeled DNA was purified with a Select-G-50 column. (5 Prime - 3 Prime, Inc. 5603 Arapahoe Road, Boulder, CO 80303). The filter was then hybridized with radioactive labeled full length CTGF-2 gene at 1,000,000 cpm/ml in 0.5 M NaP0 4 , pH 7.4 and 7% SDS overnight at 65 * C. After wash twice at room temperature and twice at 60"C with 0.5 x SSC, 0.1% SDS, the filter waε then expoεed at -70°C overnight with an intensifying screen. The mesεage RNA for CTGF-2 iε abundant in the heart. (Figure 3). Numerouε modificationε and variationε of the preεent invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

Claims: WHAT IS CLAIMED IS: 1. An isolated polynucleotide selected from the group consiεting of: (a) a polynucleotide encoding a CTGF-2 polypeptide having the deduced amino acid sequence of Figure 1 or a fragment, analog or derivative of said polypeptide; (b) a polynucleotide encoding a CTGF-2 polypeptide having the amino acid sequence encoded by cDNA contained in ATCC Deposit No. 75804 or a fragment, analog or derivative of said polypeptide. 2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA. 3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA. 4. The polynucleotide of Claim 1 wherein the polynucleotide is genomic DNA. 5. The polynucleotide of Claim 2 wherein said polynucleotide encodes CTGF-2 having the deduced amino acid sequence of Figure 1. 6. The polynucleotide of Claim 2 wherein said polynucleotide encodes a CTGF-2 polypeptide encoded by the cDNA of ATCC Deposit No. 75804. 7. The polynucleotide of Claim 1 having the coding sequence of CTGF-2 as shown in Figure 1. 8. The polynucleotide of Claim 2 having the coding sequence of CTGF-2 deposited as ATCC Deposit No. 75804. 9. A vector containing the DNA of Claim 2. 10. A host cell genetically engineered with the vector of Claim 9. 11. A procesε for producing a polypeptide comprising: expressing from the host cell of Claim 10 the polypeptide encoded by said DNA. 12. A proceεε for producing cellε capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 9. 13. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having CTGF-2 activity. 14. A polypeptide selected from the group consisting of (i) a CTGF-2 polypeptide having the deduced amino acid sequence of Figure 1 and fragmentε, analogs and derivatives thereof and (ii) a CTGF-2 polypeptide encoded by the cDNA of ATCC Deposit No. 75804 and fragmentε, analogs and derivatives of said polypeptide. 15. The polypeptide of Claim 14 wherein the polypeptide is CTGF- 2 having the deduced amino acid sequence of Figure 1. 16. An antibody against the polypeptide of claim 14. 17. An antagonist/inhibitor againεt the polypeptide of claim 14. 18. A method for the treatment of a patient having need of CTGF- 2 compriεing: administering to the patient a therapeutically effective amount of the polypeptide of claim 14. 19. A method for the treatment of a patient having need to inhibit CTGF-2 comprising: administering to the patient a therapeutically effective amount of the antagonist/inhibitor of Claim 17. 20. The method of Claim 18 wherein εaid therapeutically effective amount of the polypeptide iε administered by providing to the patient DNA encoding said polypeptide and expresεing εaid polypeptide in vivo .

Inventors: ADAMS MARK D, LI HAODONG, ADAMS, MARK, D., LI, HAODONG
Applicants: ADAMS MARK D, HUMAN GENOME SCIENCES INC, LI HAODONG, ADAMS, MARK, D., HUMAN GENOME SCIENCES, INC., LI, HAODONG
Application year: 1994
Main classification: C12N15
IPC codes: A61K8, A61K38, A61K48, A61P17, A61P35, A61P43, A61Q19, C07K14, C12N5, C12N15, C12P21, C12R1